Three Novel Myeloma Therapies: Register Now for the Myeloma Crowd Round Table Webcast on April 24
Melflufen, Ide-cel CAR T, Venetoclax
Two new drug treatments have recently been approved for myeloma by the U.S. Food and Drug Administration (FDA) and one is currently in phase 3 trials for myeloma.
Melflufen (PEPAXTO ®) is a novel peptide-drug conjugate. Ide-cel (Abecma ®) is the first CAR T product ever to be approved for use in myeloma. Venetoclax (VENCLEXTA ®) has been shown to be effective in patients with t(11;14) and studies are ongoing.
Three myeloma experts who participated in clinical trials for each one will discuss each treatment in detail and answer questions submitted by registered viewers.
Please join us on Saturday, April 24 for a 90 minute program, beginning at 12:00 pm Eastern Standard Time (9 am Pacific, 10 am Mountain, 11 am Central, 17:00 GMT, 18:00 CET). Our speakers will be:
- Jonathan Kaufman, MD, Winship Cancer Institute, Emory University, Atlanta, GA
- Michaela Liedtke, MD, Stanford University Medical Center, Palo Alto, CA
- Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC
If you have any questions, please contact Greg Brozeit at firstname.lastname@example.org or call 330-990-1090.
Recent articles on newly approved therapies:
Thanks to our Round Table sponsors
. . .